Last reviewed · How we verify

NCT06581731

Comparison of Remifentanil with a Combination of Remimazolam and Dexmedetomidine for Awake Tracheal Intubation

Recruiting now NA Last updated 23 September 2024
What this trial tests

NA trial testing remimazolam combined with remifentanil in Difficult or Failed Intubation in 60 participants. Currently enrolling.

Timeline
19 September 2024
Primary endpoint
10 September 2025
20 October 2025

Quick facts

Lead sponsorNanjing First Hospital, Nanjing Medical University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment60
Start date19 September 2024
Primary completion10 September 2025
Estimated completion20 October 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Adults 18 to 65, any sex, with Difficult or Failed Intubation or Sedative Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Awake fiberoptic intubation (AFOI) requires airway surface anesthesia to inhibit pharyngeal reflex, glottis closure reflex, and cough reflex. Additionally, the use of sedative drugs can enhance patient comfort and tolerance, reduce anxiety, and eliminate harmful effects on systemic hemodynamics.The objective of this study is to compare the safety and efficacy of remifentanil alone versus a combination of dexmedetomidine and remifentanil for sedation during conscious tracheal intubation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Difficult or Failed Intubation

Currently open trials in the same condition.

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06581731.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing